Rotavirus Infections Clinical Trial
Official title:
Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants
Verified date | September 2015 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study was designed to evaluate consistency in the antibody response to three manufactured lots of an investigational Rotavirus Vaccine.
Status | Completed |
Enrollment | 793 |
Est. completion date | August 2004 |
Est. primary completion date | August 2004 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 6 Weeks to 12 Weeks |
Eligibility |
Inclusion Criteria: - Healthy infants Exclusion Criteria: - History of abdominal disorders from a birth defect, intussusception, or abdominal surgery - Known or suspected problems with the immune system - Fever at time of immunization - Prior administration of a rotavirus vaccine - History of known prior rotavirus disease, chronic diarrhea, or failure to thrive. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Geometric Mean Antibody Titer(s) (GMT) to Serum Anti-rotavirus Immunoglobulin A (IgA). | Post Dose 3 serum samples were assayed for serum anti-rotavirus IgA | 42 days following the 3rd vaccination | No |
Other | Number of Subjects With Clinical Adverse Experiences (CAEs) | Subjects in this study were followed for all CAEs, including intussusception. A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | Yes |
Other | Number of Subjects With Serious Clinical Adverse Experiences (SCAEs) | Subjects were followed for all SCAEs. SCAEs are any CAEs occurring at any dose that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose. | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | Yes |
Other | Number of Subjects With Vaccine-Related Clinical AEs (CAEs) | CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator, who is a qualified physician, as being related to the vaccine according to his/her best clinical judgment. | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | Yes |
Other | Number of Subjects With Serious Vaccine-Related Clinical AEs (CAEs) | Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | Yes |
Other | Number of Subjects Discontinued Due to Clinical Adverse Experiences | A CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | Yes |
Other | Number of Subjects Discontinued Due to Vaccine-Related Clinical Adverse Experiences (CAEs) | CAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product. Vaccine-related CAEs are CAEs that are assessed by an investigator who is a qualified physician as being related to the vaccine according to his/her best clinical judgment. | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | Yes |
Other | Number of Subjects Discontinued Due to Serious Clinical Adverse Experiences (SCAEs) | SCAEs are any CAEs that: results in death; or is life threatening; or results in persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose. | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | No |
Other | Number of Subjects Discontinued Due to Serious Vaccine-related Clinical Adverse Experiences (CAEs) | Serious vaccine-related CAEs are CAEs assessed by an investigator as being related to the vaccine that; results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is cancer; or is an overdose. | Up to 42 days following each study vaccination, or until the time of the subsequent study vaccination(s), whichever occurred first | No |
Primary | Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8] | Antibody response to 3 manufactured lots of RotaTeq™ and placebo groups, based on the SNA PostDose 3 geometric mean titers (GMTs) (expressed in dilution units) against rotavirus serotypes G1, G2, G3, G4 and P1A[8] | 42 days following the 3rd vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02538211 -
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
|
N/A | |
Completed |
NCT02220439 -
Does the Fecal Microbiome Influence Rotarix Immunogenicity
|
N/A | |
Withdrawn |
NCT00757926 -
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT00484952 -
Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From Israel
|
N/A | |
Completed |
NCT00092443 -
Dose Confirmation Efficacy Study (V260-007)
|
Phase 3 | |
Terminated |
NCT01357174 -
ROTATEQ™ Post-Marketing Surveillance in the Philippines
|
N/A | |
Recruiting |
NCT01363726 -
Surveillance of Rotavirus Gastroenteritis in Children <5 Years
|
N/A | |
Completed |
NCT00130832 -
Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)
|
Phase 3 | |
Recruiting |
NCT06080906 -
Phase II Clinical Trial of the Inactivated Rotavirus Vaccine
|
Phase 2 | |
Recruiting |
NCT03313128 -
SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance
|
||
Completed |
NCT02542462 -
Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
|
Phase 4 | |
Completed |
NCT00346892 -
To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV
|
Phase 2 | |
Not yet recruiting |
NCT05212935 -
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
|
||
Completed |
NCT00981669 -
Rotavirus Vaccine Produced by Butantan Institute
|
Phase 1 | |
Completed |
NCT05037435 -
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.
|
Phase 3 | |
Completed |
NCT03483116 -
A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine
|
Phase 2 | |
Completed |
NCT03870061 -
Evaluation of an Infant Immunization Encouragement Program in Nigeria
|
N/A | |
Active, not recruiting |
NCT05621655 -
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
|
Phase 2 | |
Completed |
NCT00280111 -
Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants
|
Phase 1 | |
Completed |
NCT00090233 -
Rotavirus Efficacy and Safety Trial (REST)(V260-006)
|
Phase 3 |